FLASH TALKS SESSION

Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: An up to 3-year interim analysis

Presenting author: Dr Paul K. Keith

FLASH TALKS SESSION

The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States

Presenting author: Prof. Marc A. Riedl

FLASH TALKS SESSION

Attack-free probability modeling of garadacimab long-term prophylaxis for hereditary angioedema

Presenting author: Dr Philip H. Li